Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02653755 · ClinicalTrials.gov registry record · Phase 2
The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer
A Phase 2 study of Breast Cancer Radiation, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 671
- Enrollment target
- 6
- Study locations
NCT02653755 is a Phase 2 study of Breast Cancer Radiation that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 671 participants. The trial reports 6 study locations across 4 states.
The verdict
NCT02653755, a Phase 2 study of Breast Cancer Radiation, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 671 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is a way of gaining new knowledge about whether patients can omit radiation treatment after undergoing a lumpectomy, also known as "breast conserving surgery". In this trial, we are attempting to identify which patients may not need radiation.
Conditions Studied
Interventions
- DEVICE Prosigna
Study Locations (6)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
New York
- NYU Langone Health - New York
- Memorial Sloane Kettering Cancer Center - New York
Maryland
- Johns Hopkins - Baltimore
Rhode Island
- Lifespan Cancer Institute - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 671 participants |
| Start Date | 2016-05 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02653755
The ClinicalTrials.gov registry entry for NCT02653755 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 671 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer Radiation appearing as the primary indexed condition, and to 1 intervention - of which Prosigna is the first listed.
NCT02653755 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, New York, Maryland.
Frequently Asked Questions
What is clinical trial NCT02653755 about?
NCT02653755 is a clinical study titled "The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer". This research study is a way of gaining new knowledge about whether patients can omit radiation treatment after undergoing a lumpectomy, also known as "breast conserving surgery". In this trial, we are attempting to identify which patients may not need radiation.
What is the current status of trial NCT02653755?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 671 participants. The study started on 2016-05. Estimated completion is 2026-05.
What conditions does trial NCT02653755 study?
This clinical trial studies the following conditions: Breast Cancer Radiation.
What interventions are being tested in trial NCT02653755?
The interventions under investigation include: Prosigna (DEVICE).
Who is sponsoring clinical trial NCT02653755?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02653755 being conducted?
This trial has 6 study locations across Maryland, Massachusetts, New York, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.